BriaCell Therapeutics Corp.
BCT.TO
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -155.67% | -72.99% | -449.14% | -224.13% | 8.05% |
| Total Depreciation and Amortization | -17.59% | 0.09% | 27.45% | 903.29% | 752.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.50% | 93.64% | 99.78% | 85.95% | 13.49% |
| Change in Net Operating Assets | -135.98% | -91.02% | -127.04% | -156.24% | 280.17% |
| Cash from Operations | -40.79% | -23.19% | -16.76% | 22.37% | 29.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.07% | -2,448.67% | -3,298.22% | -13.33% | -- |
| Cash from Investing | 65.32% | -910.31% | -1,021.44% | -216.36% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 159.98% | 104.45% | 928.50% | 807.76% | 439.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 159.98% | 104.45% | 928.50% | 807.76% | 439.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,122.26% | 60.80% | 147.24% | 142.32% | 95.48% |